Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 26:11:1282697.
doi: 10.3389/fvets.2024.1282697. eCollection 2024.

Safety assessment of equine allogeneic tenogenic primed mesenchymal stem cells in horses with naturally occurring tendon and ligament injuries

Stephanie Carlier  1   2   3 , Eva Depuydt  4 , Lore Van Hecke  4 , Ann Martens  2 , Jimmy Saunders  3 , Jan H Spaas  3   5
Affiliations

Safety assessment of equine allogeneic tenogenic primed mesenchymal stem cells in horses with naturally occurring tendon and ligament injuries

Stephanie Carlier et al. Front Vet Sci. .

Abstract

Background: Mesenchymal stem cells provide a valuable treatment option in orthopedic injuries in horses.

Objectives: The aim of this study was to evaluate the hematological, biochemical, immunological and immunomodulatory parameters following intralesional treatment with tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells (tpMSCs) in client-owned horses with naturally occurring superficial digital flexor tendon (SDFT) and suspensory ligament (SL) injuries.

Methods: The immunogenicity and immunomodulatory capacities of tpMSCs were assessed in a modified mixed lymphocyte reaction, including peripheral blood mononuclear cells (PBMCs) of 14 horses with SDFT and SL injuries after treatment with tpMSCs. In a second study, 18 horses with SDFT and SL injuries received either an intralesional injection with tpMSCs (n = 9) or no treatment (n = 9).

Results: The tpMSCs did not provoke a cellular immune response (p < 0.001) and were able to immunomodulate stimulated T lymphocytes (p < 0.001) in vitro. Therapeutic use of tpMSCs did not result in relevant hematologic or biochemical abnormalities.

Main limitations: Both studies had a small sample size. No statistical analyses were performed in the second study. Fibrinogen was only analyzed in a single horse prior to treatment.

Conclusion: Co-incubation of tpMSCs and PBMCs of horses that have been previously exposed to tpMSCs did not elicit a cellular immune response and tpMSCs were able to immunomodulate stimulated T lymphocytes. Intralesional treatment with tpMSCs did not provoke abnormal changes in hematological and biochemical parameters.

Keywords: desmitis; equine; mesenchymal stem cell; primed MSCs; tendonitis.

PubMed Disclaimer

Conflict of interest statement

SC, ED, LV, and JHS were employed by Boehringer-Ingelheim or an affiliated company at the time of the study. The content of this manuscript contains a commercially available stem cell product (RenuTend©) owned and patented by Boehringer-Ingelheim. The funder had the following involvement in the study: the studies were performed to collect additional data for Marketing Authorization. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. One of the authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Mean PBMC proliferation (%) of equine PBMCs, stimulated PBMCs, immunogenicity (PBMCs + tpMSCs) and immunomodulation (stimulated PBMCs + tpMSCs). *p values ≤0.05.
Figure 2
Figure 2
The mean values of red blood cells, hematocrit, platelets and white bloodcells.
Figure 3
Figure 3
Biochemistry: mean values of fibrinogen (A), creatinine (B), total bilirubin (C), SAA (D) and albumin (E) of the horses treated with tpMSCs and horses that received no treatment (control). *On day 0, fibrinogen was only analyzed in a single horse.
See this image and copyright information in PMC

References

    1. Geburek F, Roggel F, Van Schie HTM, Beineke A, Estrada R, Weber K, et al. . Effect of single intralesional treatment of surgically induced equine superficial digital flexor tendon core lesions with adipose-derived mesenchymal stromal cells: a controlled experimental trial. Stem Cell Res Ther. (2017) 8:129. doi: 10.1186/s13287-017-0564-8, PMID: - DOI - PMC - PubMed
    1. Sloet Van Oldruitenborgh-Oosterbaan MM, Genzel W, van Weeren PR. A pilot study on factors influencing the career of Dutch sport horses. Equine Vet J. (2010) 42:28–32. doi: 10.1111/j.2042-3306.2010.00251.x, PMID: - DOI - PubMed
    1. Murray RC, Dyson SJ, Tranquille C, Adams V. Association of type of sport and performance level with anatomical site of orthopaedic injury diagnosis. Equine Vet J. (2006) 38:411–6. doi: 10.1111/j.2042-3306.2006.tb05578.x - DOI - PubMed
    1. Williams RB, Harkins LS, Hammond CJ, Wood JLN. Racehorse injuries, clinical problems and fatalities recorded on British racecourses from flat racing and National Hunt racing during 1996, 1997 and 1998. Equine Vet J. (2001) 33:478–86. doi: 10.2746/042516401776254808, PMID: - DOI - PubMed
    1. Johnston AS, Riggs CM, Cogger N, Benschop J, Rogers CW, Rosanowski SM. Using time-series analysis techniques to enhance the understanding of musculoskeletal injury in thoroughbred racehorses. Equine Vet J. (2020) 52:699–708. doi: 10.1111/evj.13220, PMID: - DOI - PubMed

LinkOut - more resources